SCHEDULE: Venrock Discloses 6.2% Stake in Relmada Therapeutics
Schedule 13G
Venrock Healthcare Capital Partners and affiliates have reported a 6.2% beneficial ownership stake in Relmada Therapeutics, Inc.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P. collectively hold 6,508,433 shares of Relmada Therapeutics, Inc. common stock.
- The reported holdings represent a 6.2% ownership stake in the company.
- The filing confirms that these securities are held for investment purposes and not to influence or change control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional ownership levels.
Positives
- Institutional backing from a specialized healthcare investment firm like Venrock often signals confidence in the company's long-term clinical or commercial prospects.
Negatives
- None identified in this regulatory disclosure.
Risks
- The investment is subject to market volatility and the inherent risks associated with biotechnology and pharmaceutical development.
Future Outlook
The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that this filing represents a standard institutional disclosure of a significant position in a biotech firm, which is common for venture-backed life sciences companies as they progress through clinical trials.
Comparison to Industry Standards
- The filing follows standard SEC requirements for institutional investors exceeding the 5% ownership threshold.
- The use of a Joint Filing Agreement is standard practice for affiliated investment entities to streamline regulatory reporting.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Bong Koh and Nimish Shah granted power of attorney to Jessica Baron, Evan W. Neu, and Sherman G. Souther, Jr. for SEC filings. | 06/09/2026 | Administrative change to facilitate efficient regulatory compliance. |
Stakeholder Impact
- Shareholders may view the continued presence of a major healthcare-focused investment firm as a sign of stability.
Next Steps
- The reporting persons will continue to monitor their investment in Relmada Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 05/11/2026 | Date used for total shares outstanding calculation. |
| 05/13/2026 | Date of Issuer's registration statement on Form S-3. |
| 06/02/2026 | Date of event requiring the filing of this statement. |
| 06/09/2026 | Date of execution for the Schedule 13G and associated Power of Attorney documents. |
Keywords
Relmada Therapeutics, Venrock, Schedule 13G, Biotech, Institutional Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.